Table 1.

The 28 CIPA Compounds Categorized Based on High, Intermediate, and Low Risk for Clinical TdP Were Used in the Present Study

	Generic Name	Free Cmax	Drug Concentration in µM
High risk	Azimilide	0.07	0.01	0.1	1	10
	Bepridil	0.032	0.01	0.1	1	10
	d,l-Sotalol	15	0.1	1	10	100
	Disopyramide	0.7	0.1	1	10	100
	Dofetilide	0.002	0.0003	0.001	0.003	0.01
	Ibutilide	0.1	0.0001	0.001	0.01	0.1
	Quinidine	3	1	3	9.5	30
	Vandetanib	0.3	0.01	0.1	1	10
Intermediate risk	Astemizole	0.0003	0.0001	0.001	0.01	0.1
	Chlorpromazine	0.0345	0.1	0.3	0.9	3
	Cisapride	0.00258	0.003	0.01	0.03	0.1
	Clarithromycin	1.21	0.1	1	10	100
	Clozapine	0.071	0.1	0.3	0.9	3
	Domperidone	0.02	0.003	0.03	0.3	3
	Droperidol	0.016	0.03	0.1	0.3	1
	Ondansetron	0.37	0.03	0.3	3	30
	Pimozide	0.00043	0.001	0.003	0.01	0.03
	Risperidone	0.0018	0.003	0.01	0.03	0.1
	Terfenadine	0.00029	0.001	0.01	0.1	1
Low risk	Diltiazem	0.13	0.01	0.1	1	10
	Loratadine	0.00045	0.001	0.003	0.01	0.03
	Metoprolol	1.8	3	10	32	100
	Mexiletine	2.5	0.1	1	10	100
	Nifedipine	0.0077	0.001	0.01	0.1	1
	Nitrendipine	0.0030	0.01	0.03	0.1	0.3
	Ranolazine	1.95	0.1	1	10	100
	Tamoxifen	0.021	0.1	0.3	1	3
	Verapamil	0.045	0.001	0.01	0.1	1

The free C_max level and concentrations were selected based on the HESI/CIPA stem-cell group studies (Blinova et al., 2018).